Literature DB >> 19615304

Managing dyspepsia.

Alexander C Ford1, Paul Moayyedi.   

Abstract

The prevalence of dyspepsia in the general population is as high as 40%, and its management represents a considerable financial burden to the health care system. Causes of dyspepsia amenable to medical therapy include peptic ulcer and functional dyspepsia, and testing for Helicobacter pylori and treating positive individuals is beneficial in both conditions. Individuals presenting for the first time with uninvestigated dyspepsia, age greater than 50 years, or alarm features require upper gastrointestinal (GI) endoscopy to exclude gastroesophageal malignancy. Upper GI endoscopy for younger individuals without alarm features is not cost-effective compared with the "test and treat" approach. Test and treat and empirical acid-suppression using a proton pump inhibitor (PPI) have similar costs and effects. Recent evidence suggests that empirical acid suppression commencing with antacids is as effective as PPI. Screening and treatment of H. pylori in PPI users and the community may reduce the costs of managing dyspepsia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19615304     DOI: 10.1007/s11894-009-0042-2

Source DB:  PubMed          Journal:  Curr Gastroenterol Rep        ISSN: 1522-8037


  50 in total

1.  Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment.

Authors:  E A Rauws; W Langenberg; H J Houthoff; H C Zanen; G N Tytgat
Journal:  Gastroenterology       Date:  1988-01       Impact factor: 22.682

2.  Randomised controlled trial of Helicobacter pylori testing and endoscopy for dyspepsia in primary care.

Authors:  B C Delaney; S Wilson; A Roalfe; L Roberts; V Redman; A Wearn; F D Hobbs
Journal:  BMJ       Date:  2001-04-14

3.  Effect of population screening and treatment for Helicobacter pylori on dyspepsia and quality of life in the community: a randomised controlled trial. Leeds HELP Study Group.

Authors:  P Moayyedi; R Feltbower; J Brown; S Mason; J Mason; J Nathan; I D Richards; A C Dowell; A T Axon
Journal:  Lancet       Date:  2000-05-13       Impact factor: 79.321

4.  A randomised controlled trial of four management strategies for dyspepsia: relationships between symptom subgroups and strategy outcome.

Authors:  N T Lewin van den Broek; M E Numans; E Buskens; T J Verheij; N J de Wit; A J Smout
Journal:  Br J Gen Pract       Date:  2001-08       Impact factor: 5.386

Review 5.  The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis.

Authors:  Paul Moayyedi; Brendan C Delaney; Nimish Vakil; David Forman; Nicholas J Talley
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 6.  Functional gastroduodenal disorders.

Authors:  Jan Tack; Nicholas J Talley; Michael Camilleri; Gerald Holtmann; Pinjin Hu; Juan-R Malagelada; Vincenzo Stanghellini
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

7.  Helicobacter pylori "test and treat" or endoscopy for managing dyspepsia: an individual patient data meta-analysis.

Authors:  Alexander C Ford; Michelle Qume; Paul Moayyedi; Nicolaas L A Arents; Annmarie T Lassen; Richard F A Logan; Kenneth E L McColl; Paul Myres; Brendan C Delaney
Journal:  Gastroenterology       Date:  2005-06       Impact factor: 22.682

Review 8.  An update of the Cochrane systematic review of Helicobacter pylori eradication therapy in nonulcer dyspepsia: resolving the discrepancy between systematic reviews.

Authors:  Paul Moayyedi; Jon Deeks; Nicholas J Talley; Brendan Delaney; David Forman
Journal:  Am J Gastroenterol       Date:  2003-12       Impact factor: 10.864

Review 9.  Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis.

Authors:  Alexander C Ford; Brendan C Delaney; David Forman; Paul Moayyedi
Journal:  Am J Gastroenterol       Date:  2004-09       Impact factor: 10.864

Review 10.  Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis.

Authors:  A C Ford; N J Talley; P S Schoenfeld; E M M Quigley; P Moayyedi
Journal:  Gut       Date:  2008-11-10       Impact factor: 23.059

View more
  4 in total

1.  Duodenal epithelial transport in functional dyspepsia: Role of serotonin.

Authors:  Anne-Barbara Witte; Mauro D'Amato; Steen Seier Poulsen; Agneta Laurent; Svend Knuhtsen; Niels Bindslev; Mark Berner Hansen; Peter Thelin Schmidt
Journal:  World J Gastrointest Pathophysiol       Date:  2013-05-15

2.  The role of Helicobacter pylori infection in functional dyspepsia.

Authors:  Theodore Rokkas
Journal:  Ann Gastroenterol       Date:  2012

Review 3.  Acupuncture for Functional Dyspepsia: What Strength Does It Have? A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Authors:  Bo Pang; Tao Jiang; Yuan-Hao Du; Jing Li; Bo Li; Ya-Cai Hu; Qiu-Han Cai
Journal:  Evid Based Complement Alternat Med       Date:  2016-12-29       Impact factor: 2.629

4.  Inflammation at the crossroads of Helicobacter pylori and COVID-19.

Authors:  Ileana Gonzalez; Cristian Lindner; Ivan Schneider; Miguel A Morales; Armando Rojas
Journal:  Future Microbiol       Date:  2021-12-17       Impact factor: 3.165

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.